Cargando…
Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy
SIMPLE SUMMARY: Anti-CD38 monoclonal antibody has improved the prognosis of relapsed/refractory multiple myeloma (RRMM) but some patients still experience early relapse with a poor outcome. We have here evaluated the predictive value of FDG PET/CT parameters prior to receiving anti-CD38-based therap...
Autores principales: | Fouquet, Guillemette, Wartski, Myriam, Dechmi, Amina, Willems, Lise, Deau-Fischer, Bénédicte, Franchi, Patricia, Descroocq, Justine, Deschamps, Paul, Blanc-Autran, Estelle, Clerc, Jérôme, Bouscary, Didier, Barreau, Sylvain, Chapuis, Nicolas, Vignon, Marguerite, Cottereau, Anne-Ségolène |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431719/ https://www.ncbi.nlm.nih.gov/pubmed/34503133 http://dx.doi.org/10.3390/cancers13174323 |
Ejemplares similares
-
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma
por: Henriquez, Soledad, et al.
Publicado: (2022) -
Subcutaneous azacitidine maintenance in transplant-ineligible patients with acute myeloid leukemia: a single-center retrospective study
por: Johnson, Natacha, et al.
Publicado: (2023) -
Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era
por: Zerbit, Jeremie, et al.
Publicado: (2022) -
Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis
por: Vazquez, Romain, et al.
Publicado: (2021) -
Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients
por: Birsen, Rudy, et al.
Publicado: (2018)